A recent study indicates that patients who stop using blockbuster slimming jabs like semaglutide or tirzepatide may regain shed pounds much more quickly than those who stop conventional diet and exercise plans.
Research printed in a leading health publication points out that while overweight individuals frequently drop a large proportion of their total mass while using the jabs, the weight comes back at an average rate of nearly a kilo each month after stopping.
"Individuals using these drugs should be cognizant of the potential of rapid weight regain when the medication concludes," warns lead investigator Dr. Susan Jebb.
That rate of recovery suggests a return to original weight in about 18 months.
Comparing Therapies
The analysis, which examined dozens of studies involving over 9,000 of patients, contrasted the results of GLP-1 agonists with other pills.
The team emphasize that people who shed pounds through diet and exercise generally see a less rapid creep back—approximately 100 grams monthly—once they finish.
Understanding the Fast Rebound
Experts believe the mechanism of the injections explains the amplified regain.
GLP-1 drugs copy a body's own chemical called GLP-1, which helps regulate appetite.
"Sustained high doses of GLP-1 levels far above than normal might result in the system to produce less of its endogenous GLP-1, and could lessen sensitivity to its effects," noted Dr. Adam Collins, a nutrition expert.
"Discontinuation of this GLP-1 'fix' results in appetite is unsuppressed, making binge eating a significant risk."
A Chronic Disease?
Health authorities recommend the injections for individuals with weight-linked health risks, alongside recommended lifestyle changes.
A number of clinicians argue that, due to the likelihood of relapse, the therapy should be considered long-term.
This opinion is reinforced by drug manufacturers, who note that the results "emphasize the persistent nature of obesity," comparing it to managing diseases like diabetes.
Patient Testimonies
Users who have discontinued the medication describe a intense resurgence of hunger.
"I experienced a trigger that goes on and you become ravenous," recalled a patient.
This difficulty is worsened if users have not developed sustainable dietary or behavioural changes during treatment.
Significant Use
Figures suggest that millions of people in the UK have used these injections in the past year, with desire remaining high.
- Adoption is greater among women compared to men.
- The 40s and 50s demographic shows the highest level of interest.
- A large proportion obtain the medications through private prescriptions rather than public health services.
In conclusion, clinicians caution that while these medications are effective agents for weight loss, they are not a standalone cure and maintained weight loss relies on ongoing lifestyle management.
